Topics

Companies Related to "Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique?" [Most Relevant Company Matches] RSS

19:09 EDT 19th July 2019 | BioPortfolio

Here are the most relevant search results for "Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique?" found in our extensive corporate database of over 50,000 company records.

Showing "Does fire Technique Increase Detection Rate Prostate Cancer" Companies 1–25 of 3,400+

Extremely Relevant

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.


Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...


Onconome, Inc.

Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...

Relevant

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

Mitomics

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests...

RC Cancer Centers

Each year thousands of patients from around the world and across the United States turn to RC Cancer Centers seeking a cure for their prostate cancer and learn why they are The Choice for Saving Lives. Founded in 1979, Radiotherapy Centers of Georgia, a division of RC Cancer Centers, has earned a reputation for being one of the country's top cancer treatment and research facilities because of its ...

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

KOELIS

KOELIS offers new concepts for the management of prostate cancer. As the inventor of image fusion for prostate cancer, KOELIS has brought a unique, accurate and rapid solution that guarantees high quality control at each stage of diagnosis. Since 2006, more than 250,000 patients across the world have benefited from KOELIS’ technology. KOELIS has estab...

Us TOO International

Us TOO is a nonprofit organization founded in 1990 that provides educational resources and support services to the prostate cancer community at no charge to help men and their spouses/partners and loved ones make informed decisions about prostate cancer detection, treatment options and related side effects. In addition to more than 200 support groups throu...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by ident...

Akrivis Technologies LLC

Akrivis Technologies, LLC is a privately held company headquartered in Cambridge, Massachusetts, committed to the early detection, diagnosis and treatment of serious and life-threatening diseases based on its patented Z-TECTTM technology platform. Z-TECTTM is a new nanotechnology-based technique for detecting unusually low levels of protein and molecular ...

National Breast Cancer Awareness Month

In the United States, an estimated 192,370 women and 1,910 men will be diagnosed with new cases of breast cancer in 2009. Breast cancer ranks second as a cause of cancer death in women (after lung cancer). Death rates for breast cancer have steadily decreased in women since 1990, due to progress in both earlier detection and improved treatment. The current five-year survival rate for female breast...

iCAD Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and comp...

iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography...

Signet Laboratories Incorporated

Signet Laboratories, Inc is a medical biotechnology company focused in fields of cancer and infectious disease(Sepsis). Signet has developed proprietary antibody systems for the detection and management of breast and prostate cancer and Sepsis. Signet's patented technology will provide for determining risk in "normal patients who may be at increased risk for developing cancer at a time when proac...

Coalition to Cure Prostate Cancer

The Coalition to Cure Prostate Cancer is a philanthropic organization that funds and accelerates advanced prostate cancer research in Canada. Beginning in 2011, the Coalition has identified unique strategies to invest in the most promising research programs that generate life-saving results. By channeling resources to Canada’s top scientific minds, red ...

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...

Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...

GammaWest Brachytherapy

Brachytherapy is an advanced cancer treatment. The word "brachy" is Greek for "close by" and refers to placing radioactive seeds or sources directly in the tumor. This procedure gives physicians and patients the important advantage of applying a higher dose of radiation directly to the tumor while sparing healthy tissue and surrounding organs. Brachytherapy is a localized, precise, radiation treat...

Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic....

EA Biotech Ltd

EA Biotech Ltd. was set up in 1998 by Frank Fox, after 27 years of experience working in the commercial sector as an instrumentation engineer with a large scientific instrument supplier. The Enhanced Autoradiography technique was developed as a solution to the problem of low detection sensitivity inherent in many autoradiographic detection processes in widespread use in the research and developmen...

ImmunSYS, Inc.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energ...


More From BioPortfolio on "Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique?"

Quick Search

Corporate Database Quicklinks